Form 8-K - Current report:
SEC Accession No. 0001193125-22-206598
Filing Date
2022-07-29
Accepted
2022-07-29 16:05:22
Documents
12
Period of Report
2022-07-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d378391d8k.htm   iXBRL 8-K 21594
  Complete submission text file 0001193125-22-206598.txt   146140

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA xfor-20220725.xsd EX-101.SCH 2861
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE xfor-20220725_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xfor-20220725_pre.xml EX-101.PRE 11711
6 EXTRACTED XBRL INSTANCE DOCUMENT d378391d8k_htm.xml XML 3470
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 221120774
SIC: 2836 Biological Products, (No Diagnostic Substances)